Treatment includes teprotumumab which blocks IGF-1R activation, it's approved by the FDA for the treatment of thyroid eye disease.

治疗手段包括Teprotumumab，可阻断IGF-1R的激活，在美国已被FDA批准用于甲状腺眼病的治疗。